Genomic and computational analysis of four novel variants of MPL gene in Congenital Amegakaryocytic Thrombocytopenia
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
Congenital amegakaryocytic thrombocytopenia (CAMT) is a rare, genetic, autosomal recessive disorder characterized by severe thrombocytopenia, due to inefficient bone marrow megakaryopoiesis eventually leading to aplasia. Majority of the cases are due to homozygous or compound heterozygous mutations in MPL gene encoding for thrombopoietin (THPO) receptor protein. CAMT can be diagnosed at early phase of life, with major complication of transfusion dependency and hematopoietic transplantation as only curative treatment. We have investigated the sequence variations in MPL gene of 7 bone marrow failure (BMF) subjects, who presented with clinically diverse phenotypes, through next generation sequencing (NGS). Plasma THPO levels were estimated using ELISA. Insilico sequence and structure-based analyses were performed to understand the structural and functional implications of mutations, identified through NGS. We studied 7 CAMT subjects suspected of BMF, who presented with severe thrombocytopenia followed by pancytopenia, bleeding manifestation and physical anomalies. The plasma THPO levels were significantly elevated (p<0.05) in all the cases. Molecular analysis by NGS identified 9 genomic mutations in MPL gene. These included 7 non-synonymous substitution, 1 nonsense substitution and 1 in-del mutations, of which 4 are novel mutations. Insilico analysis predicted damaging effects on THPO-R and its reduced affinity for THPO for all the identified mutations. CAMT is a rare disorder with diverse clinical phenotypes and diagnosis is challenging. The elevated plasma THPO levels should be considered for the primary diagnosis and prognosis of the disease. However, molecular analysis of MPL gene is important for the diagnosis and management of the disease through genetic counselling. Though the cytokines, THPO-R agonist are used for the treatment of CAMT, HSCT is the only curative therapy.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:102 |
---|---|
Enthalten in: |
Annals of hematology - 102(2023), 10 vom: 12. Okt., Seite 2683-2693 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Shah, Anjali [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 11.09.2023 Date Revised 15.09.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1007/s00277-023-05347-7 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM359392997 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM359392997 | ||
003 | DE-627 | ||
005 | 20231226080756.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s00277-023-05347-7 |2 doi | |
028 | 5 | 2 | |a pubmed24n1197.xml |
035 | |a (DE-627)NLM359392997 | ||
035 | |a (NLM)37438490 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Shah, Anjali |e verfasserin |4 aut | |
245 | 1 | 0 | |a Genomic and computational analysis of four novel variants of MPL gene in Congenital Amegakaryocytic Thrombocytopenia |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 11.09.2023 | ||
500 | |a Date Revised 15.09.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
520 | |a Congenital amegakaryocytic thrombocytopenia (CAMT) is a rare, genetic, autosomal recessive disorder characterized by severe thrombocytopenia, due to inefficient bone marrow megakaryopoiesis eventually leading to aplasia. Majority of the cases are due to homozygous or compound heterozygous mutations in MPL gene encoding for thrombopoietin (THPO) receptor protein. CAMT can be diagnosed at early phase of life, with major complication of transfusion dependency and hematopoietic transplantation as only curative treatment. We have investigated the sequence variations in MPL gene of 7 bone marrow failure (BMF) subjects, who presented with clinically diverse phenotypes, through next generation sequencing (NGS). Plasma THPO levels were estimated using ELISA. Insilico sequence and structure-based analyses were performed to understand the structural and functional implications of mutations, identified through NGS. We studied 7 CAMT subjects suspected of BMF, who presented with severe thrombocytopenia followed by pancytopenia, bleeding manifestation and physical anomalies. The plasma THPO levels were significantly elevated (p<0.05) in all the cases. Molecular analysis by NGS identified 9 genomic mutations in MPL gene. These included 7 non-synonymous substitution, 1 nonsense substitution and 1 in-del mutations, of which 4 are novel mutations. Insilico analysis predicted damaging effects on THPO-R and its reduced affinity for THPO for all the identified mutations. CAMT is a rare disorder with diverse clinical phenotypes and diagnosis is challenging. The elevated plasma THPO levels should be considered for the primary diagnosis and prognosis of the disease. However, molecular analysis of MPL gene is important for the diagnosis and management of the disease through genetic counselling. Though the cytokines, THPO-R agonist are used for the treatment of CAMT, HSCT is the only curative therapy | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Congenital amegakaryocytic thrombocytopenia | |
650 | 4 | |a MPL gene | |
650 | 4 | |a Next generation sequencing | |
650 | 4 | |a Pancytopenia | |
650 | 4 | |a THPO-R structure | |
650 | 4 | |a Thrombopoietin | |
650 | 4 | |a Thrombopoietin receptor | |
650 | 7 | |a Thrombopoietin |2 NLM | |
650 | 7 | |a 9014-42-0 |2 NLM | |
650 | 7 | |a MPL protein, human |2 NLM | |
650 | 7 | |a 143641-95-6 |2 NLM | |
650 | 7 | |a Receptors, Thrombopoietin |2 NLM | |
700 | 1 | |a Kumar, Chandan |e verfasserin |4 aut | |
700 | 1 | |a Shanmukhaiah, Chandrakala |e verfasserin |4 aut | |
700 | 1 | |a Rajendran, Aruna |e verfasserin |4 aut | |
700 | 1 | |a Mudaliar, Sangeeta |e verfasserin |4 aut | |
700 | 1 | |a Idicula-Thomas, Susan |e verfasserin |4 aut | |
700 | 1 | |a Vundinti, Babu Rao |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Annals of hematology |d 1991 |g 102(2023), 10 vom: 12. Okt., Seite 2683-2693 |w (DE-627)NLM012918768 |x 1432-0584 |7 nnns |
773 | 1 | 8 | |g volume:102 |g year:2023 |g number:10 |g day:12 |g month:10 |g pages:2683-2693 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00277-023-05347-7 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 102 |j 2023 |e 10 |b 12 |c 10 |h 2683-2693 |